Table of Content

1. Research Methodology


2. Introduction To Orphan Drugs


3. Global Orphan Drug Designation Criteria
3.1 US
3.2 Europe
3.3 Asia & Australia


4. Market Exclusivity & Patent Protection for Orphan Drugs


5. Global Orphan Designated Cancer Drug Market
5.1 Current Market Scenario
5.2 Future Market Opportunity


6. Orphan Designated Cancer Drug Market Insight by Region
6.1 US
6.2 Europe
6.3 Japan
6.4 South Korea
6.5 China
6.6 Australia
6.7 UK
6.8 Canada
6.9 Middle East


7. Global Orphan Designated Cancer Drug Market by Indication
7.1 Lymphoma
7.2 Leukemia
7.3 Lung Cancer
7.4 Multiple Myeloma
7.5 Ovarian Cancer
7.6 Gastric Cancer
7.7 Thyroid Cancer
7.8 Liver Cancer
7.9 Pancreatic Cancer
7.10 Melanoma
7.11 Brain Cancer
7.12 Renal Cell Carcinoma


8. Top 50 Orphan Designated Cancer Drugs - Availability, Dosage, Price & Sales Forecats 2028

THIS Chapter GIVES COMPREHENISVE CLINICAL & COMMERCIAL INSIGHT ON TOP 50 ORPHAN DESIGNATED CANCER DRUGS. THESE DRUGS ACCOUNT FOR MORE THAN 70% OF TOTAL ORPHAN DESIGNATED CANCER DRUG MARKET. MORE THAN 500 CHARTS & GRAPHS REPRESENTING SALES, PATENT, PRICING, DOSAGE, APPROVAL YEAR INSIGHT ON TOP 50 ORPHNA DESIGNATED CANCER DRUGS.


9. Global Orphan Cancer Drugs Clinical Pipeline Overview
9.1 By Company
9.2 Drug Class
9.3 Indication
9.4 Priority Status
9.5 By Phase


10. Global Orphan Cancer Drugs Clinical Pipeline By Company, Country , Indication & Phase
10.1 Preclinical
10.2 Phase-I
10.3 Phase-I/II
10.4 Phase-II
10.5 Phase-II/III
10.6 Phase-III
10.7 Preregistration
10.8 Registered


11. Marketed Orphan Cancer Drugs Clinical Insight By Company, Country & Indication


12. Competitive Landscape
12.1 AOP Orphan
12.2 Agenus
12.3 Alexion
12.4 Bristol Myers Squibb
12.5 Biogen Idec
12.6 Celgene
12.7 Eli Lilly
12.8 Genethon
12.9 Genzyme Corporation
12.10 Glaxosmithkline
12.11 Merck
12.12 Novartis Pharmaceuticals
12.13 Orphan Europe
12.14 Pfizer
12.15 Prosensa
12.16 Rare Disease Therapeutics
12.17 Roche
12.18 Sanofi
12.19 Shire
12.20 Teva Pharmaceutical